Amyotrophic Lateral Sclerosis

News Amyotrophic Lateral Sclerosis

• Cancer drug prevents build-up of toxic brain protein

  Researchers at Georgetown University Medical Center have used tiny doses of a leukemia drug to halt accumulation of toxic proteins linked to Parkinson's disease in the brains of mice. This finding provides the basis to plan a clinical trial in humans to study the effects. They say their study, publi more

• Pitt team finds melatonin delays ALS symptom onset and death in mice

  Melatonin injections delayed symptom onset and reduced mortality in a mouse model of the neurodegenerative condition amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, according to a new study by researchers at the University of Pittsburgh School of Medicine. In a report published online more

• ALS TDI and to-BBB collaborate on potential treatments for Motor Neuron Disease

  The ALS Therapy Development Institute (ALS TDI) announced that it has entered into a new collaboration with to-BBB to investigate potential treatments for ALS (aka Motor Neuron or Lou Gehrig’s disease). The blood-brain barrier (BBB) fortifies the walls of blood vessels to prevent the entry of certai more

Publications Amyotrophic Lateral Sclerosis

• Expanded GGGGCC repeat RNA associated with amyotrophic lateral sclerosis and frontotemporal dementia causes neurodegeneration [Genetics]

  Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) share phenotypic and pathologic overlap. Recently, an expansion of GGGGCC repeats in the first intron of C9orf72 was found to be a common cause of both illnesses; however, the molecular pathogenesis of this expanded repeat is unkn more

• Hdac6 deletion delays disease progression in the SOD1G93A mouse model of ALS

  Defects in axonal transport are thought to contribute to the pathogenesis of neurodegenerative disease. Because α-tubulin acetylation facilitates axonal transport, inhibition of the α-tubulin deacetylating enzymes, histone deacetylase 6 (Hdac6) and silent information regulator 2 (Sirt2), is thought more

• Design and Initial Results of a Multi-Phase Randomized Trial of Ceftriaxone in Amyotrophic Lateral Sclerosis

  by James D. Berry, Jeremy M. Shefner, Robin Conwit, David Schoenfeld, Myles Keroack, Donna Felsenstein, Lisa Krivickas, William S. David, Francine Vriesendorp, Alan Pestronk, James B. Caress, Jonathan Katz, Ericka Simpson, Jeffrey Rosenfeld, Robert Pascuzzi, Jonathan Glass, Kourosh Rezania, Jeffrey more

Market studies Amyotrophic Lateral Sclerosis

• Amyotrophic Lateral Sclerosis Global Clinical Trials Review, H1, 2012

  Introduction GlobalData's clinical trial report, “Amyotrophic Lateral Sclerosis Global Clinical Trials Review, H1, 2012" provides data on the Amyotrophic Lateral Sclerosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Amyotrophic La more

• Amyotrophic Lateral Sclerosis – Pipeline Review, H2 2012

  Introduction Global Markets Direct’s, 'Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2012', provides an overview of the Amyotrophic Lateral Sclerosis therapeutic pipeline. This report provides information on the therapeutic development for Amyotrophic Lateral Sclerosis, complete with latest more

• Orphan Diseases Therapeutics in CNS to 2017 - Novel Agents such as AMR101 and ACR16 to Provide Treatment Options and Boost the Huntington’s Disease Segment

  GBI Research, the leading business intelligence provider, has released its latest research “Orphan Diseases Therapeutics in CNS to 2017 - Novel Agents such as AMR101 and ACR16 to Provide Treatment Options and Boost the Huntington’s Disease Segment”, which provides insights into the CNS orphan diseas more

Websites Amyotrophic Lateral Sclerosis